%0 Journal Article
%T Hepatitis B reactivation related to everolimus
%A Sema Sezgin G£¿ksu
%A £¿erife Bilal
%A Hasan £¿enol Co£¿kun
%J World Journal of Hepatology
%D 2013
%I Baishideng Publishing Group Co. Limited
%R 10.4254/wjh.v5.i1.43
%X Reactivation of hepatitis B virus (HBV) during chemotherapy is a well known complication in patients with chronic hepatitis B and cancer. The clinical manifestations range from subclinical elevation of liver enzymes to severe, potentially fatal fulminant hepatitis. Reactivation can occur in a patient with previous inactive HBV infection; either an inactive carrier or a patient with resolved hepatitis. Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved in renal cell carcinoma, neuroendocrine tumours and breast cancer. mTOR inhibitors are a new generation of drugs for targeted treatment; therefore, little about their side effects is known. Here, we report a patient with renal cell carcinoma who experienced a flare of hepatitis B infection during treatment with everolimus. Clinicians should be aware of HBV reactivation in patients who are undergoing treatment with everolimus, and screening for hepatitis B infection and prophylactic antiviral treatment should be considered.
%K Hepatitis B
%K Virus reactivation
%K Everolimus
%K Mammalian target of rapamycin inhibitors
%K Immunosuppressive treatment
%K Renal cell carcinoma
%U http://www.wjgnet.com/1948-5182/full/v5/i1/43.htm